CN107648181A - 一种利他唑酮磷脂复合物及其制备方法和应用 - Google Patents
一种利他唑酮磷脂复合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN107648181A CN107648181A CN201610589301.1A CN201610589301A CN107648181A CN 107648181 A CN107648181 A CN 107648181A CN 201610589301 A CN201610589301 A CN 201610589301A CN 107648181 A CN107648181 A CN 107648181A
- Authority
- CN
- China
- Prior art keywords
- oxazolone
- profit
- phosphatide complexes
- phosphatide
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 title claims abstract description 193
- 238000002360 preparation method Methods 0.000 title claims abstract description 61
- 239000007924 injection Substances 0.000 claims abstract description 77
- 238000002347 injection Methods 0.000 claims abstract description 77
- 239000000839 emulsion Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 35
- 229940083466 soybean lecithin Drugs 0.000 claims description 35
- 239000003921 oil Substances 0.000 claims description 30
- 235000019198 oils Nutrition 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- 239000012071 phase Substances 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000008346 aqueous phase Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 210000003022 colostrum Anatomy 0.000 claims description 14
- 235000021277 colostrum Nutrition 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 235000012424 soybean oil Nutrition 0.000 claims description 12
- 239000003549 soybean oil Substances 0.000 claims description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000005642 Oleic acid Substances 0.000 claims description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 210000000481 breast Anatomy 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 229940042880 natural phospholipid Drugs 0.000 claims description 7
- 239000006184 cosolvent Substances 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 claims description 4
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 108010048349 Steroidogenic Factor 1 Proteins 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 16
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000004530 micro-emulsion Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 229940090044 injection Drugs 0.000 description 61
- 239000003814 drug Substances 0.000 description 39
- 238000012360 testing method Methods 0.000 description 27
- 238000002390 rotary evaporation Methods 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 229940079593 drug Drugs 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 13
- 206010040047 Sepsis Diseases 0.000 description 11
- 208000013223 septicemia Diseases 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000003643 water by type Substances 0.000 description 11
- -1 Acyl monoethanolamine Chemical compound 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000006069 physical mixture Substances 0.000 description 10
- 239000012982 microporous membrane Substances 0.000 description 9
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 7
- 229960003907 linezolid Drugs 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010062255 Soft tissue infection Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- WGZCUXZFISUUPR-UHFFFAOYSA-N acetonitrile;oxolane Chemical compound CC#N.C1CCOC1 WGZCUXZFISUUPR-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940091632 linezolid injection Drugs 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229940113478 lecithin 200 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010010 raising Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100468589 Arabidopsis thaliana RH30 gene Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BYWUNUDERLAEFZ-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)[P] Chemical compound C(CCCCCCCCCCCCCCC)[P] BYWUNUDERLAEFZ-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920013747 hydroxypolyethylene Polymers 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
利他唑酮磷脂复合物(以利他唑酮计) | 50mg |
大豆油 | 10g |
MCT(中链脂肪酸甘油三酯) | 10g |
大豆磷脂 | 1.2g |
甘油 | 2.25g |
油酸 | 0.24g |
注射用水 | 至100mL |
利他唑酮磷脂复合物(以利他唑酮计) | 100mg |
大豆油 | 10g |
MCT(中链脂肪酸甘油三酯) | 10g |
蛋黄卵磷脂 | 0.6g |
油酸 | 0.24g |
ELP(Cremophor®ELP,氢化蓖麻油聚烃氧酯35) | 0.2g |
甘油 | 1.5g |
F-68(泊洛沙姆188) | 0.6g |
注射用水 | 至100mL |
利他唑酮磷脂复合物(以利他唑酮计) | 100mg |
大豆油 | 10g |
MCT(中链脂肪酸甘油三酯) | 10g |
大豆磷脂 | 1.2g |
油酸 | 0.24g |
HS15(Solutol HS15,15-羟基硬脂酸聚乙二醇酯) | 0.2g |
甘油 | 1.5g |
F68(泊洛沙姆188) | 0.6g |
注射用水 | 至100mL |
利他唑酮磷脂复合物(以利他唑酮计) | 100mg |
大豆油 | 10g |
MCT(中链脂肪酸甘油三酯) | 10g |
蛋黄卵磷脂 | 1.2g |
油酸 | 0.24g |
RH40(Cremophor® RH40,聚氧乙烯氢化蓖麻油,氢化蓖麻油聚烃氧酯40) | 0.2g |
甘油 | 1.5g |
F68(泊洛沙姆188) | 0.6g |
注射用水 | 至100mL |
实施例 | 粒径(nm) | PDI | 亚微乳含量(%) |
实施例12 | 304.2 | 0.373 | 95.30 |
实施例13 | 196.0 | 0.176 | 98.50 |
实施例14 | 185.0 | 0.156 | 99.07 |
实施例15 | 287.6 | 0.378 | 96.54 |
实施例 | 复合率 |
实施例1 | 97.62% |
实施例2 | 95.91% |
实施例3 | 90.38% |
实施例4 | 83.21% |
实施例5 | 81.58% |
实施例6 | 81.35% |
实施例7 | 85.74% |
实施例8 | 91.25% |
实施例9 | 80.55% |
实施例10 | 99.35% |
实施例11 | 91.41% |
时间/min | 溶液A/% | 溶液B/% |
0 | 60 | 40 |
10 | 60 | 40 |
20 | 20 | 80 |
24 | 20 | 80 |
25 | 60 | 40 |
30 | 60 | 40 |
样品名称 | 水(μg/mL) | 乙醇(μg/mL) | 大豆油(μg/mL) | MCT(μg/mL) |
利他唑酮 | 4.88 | 154.22 | 9.19 | 84.15 |
利他唑酮-磷脂物理混合物 | 9.25 | 186.54 | 16.87 | 136.73 |
利他唑酮磷脂复合物 | 109.52 | 2587.65 | 520.58 | 1259.33 |
试验药 | 对照药 | |
名称 | 利他唑酮磷脂复合物亚微乳注射剂 | 利奈唑胺注射液 |
批号 | 20140806-1 | 14C07U93 |
含量 | 90% | 100% |
生产厂家 | 自制 | 辉瑞制药有限公司 |
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610589301.1A CN107648181B (zh) | 2016-07-25 | 2016-07-25 | 一种利他唑酮磷脂复合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610589301.1A CN107648181B (zh) | 2016-07-25 | 2016-07-25 | 一种利他唑酮磷脂复合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107648181A true CN107648181A (zh) | 2018-02-02 |
CN107648181B CN107648181B (zh) | 2021-05-04 |
Family
ID=61127045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610589301.1A Active CN107648181B (zh) | 2016-07-25 | 2016-07-25 | 一种利他唑酮磷脂复合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107648181B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355165A (zh) * | 2001-12-19 | 2002-06-26 | 中国医学科学院医药生物技术研究所 | 3,5-取代噁唑烷酮衍生物及其制备方法和应用 |
WO2003031443A1 (en) * | 2001-10-04 | 2003-04-17 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety |
CN1713924A (zh) * | 2000-08-22 | 2005-12-28 | 法马西亚公司 | 药物含量增加的噁唑烷酮抗菌药物溶液组合物 |
CN101411686A (zh) * | 2008-12-11 | 2009-04-22 | 刘玉辉 | 克拉霉素亚微乳注射液及其制备方法 |
CN102256951A (zh) * | 2009-11-04 | 2011-11-23 | 四川贝力克生物技术有限责任公司 | 结晶水合物、药物组合物及其制备方法和用途 |
-
2016
- 2016-07-25 CN CN201610589301.1A patent/CN107648181B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1713924A (zh) * | 2000-08-22 | 2005-12-28 | 法马西亚公司 | 药物含量增加的噁唑烷酮抗菌药物溶液组合物 |
WO2003031443A1 (en) * | 2001-10-04 | 2003-04-17 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety |
CN1355165A (zh) * | 2001-12-19 | 2002-06-26 | 中国医学科学院医药生物技术研究所 | 3,5-取代噁唑烷酮衍生物及其制备方法和应用 |
CN101411686A (zh) * | 2008-12-11 | 2009-04-22 | 刘玉辉 | 克拉霉素亚微乳注射液及其制备方法 |
CN102256951A (zh) * | 2009-11-04 | 2011-11-23 | 四川贝力克生物技术有限责任公司 | 结晶水合物、药物组合物及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
李全林,等: "《新医药开发与研究 (下册)》", 31 December 2008, 中国医药科技出版社 * |
陆岩: "克拉霉素亚微乳注射液的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Also Published As
Publication number | Publication date |
---|---|
CN107648181B (zh) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109689034A (zh) | 协同抗真菌组合物及其方法 | |
CN106999598A (zh) | 稳定的大麻素类化合物制剂 | |
Ahmed et al. | Study the antifungal and ocular permeation of ketoconazole from ophthalmic formulations containing trans-ethosomes nanoparticles | |
AT509000A1 (de) | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen | |
CN106928274A (zh) | 一种双氢青蒿素二倍体衍生物、其药物组合物及应用 | |
Baldim et al. | Natural ergot alkaloids in ocular pharmacotherapy: Known molecules for novel nanoparticle-based delivery systems | |
Andrade-Carrera et al. | Cytotoxic evaluation of (2 S)-5, 7-dihydroxy-6-prenylflavanone derivatives loaded PLGA nanoparticles against MiaPaCa-2 cells | |
Xia et al. | In vitro evaluation of α-lipoic acid-loaded lipid nanocapsules for topical delivery | |
CN102210653B (zh) | 牛蒡苷元的微乳制剂 | |
CN102811706A (zh) | 紫杉醇/类固醇复合物 | |
CN105726494B (zh) | 穿心莲内酯纳米混悬剂组合物及其制备方法和应用 | |
DE112014001876T5 (de) | Vitamin-funktionalisierte Gel-bildende Blockcopolymere für biomedizinische Anwendungen | |
CN104352566A (zh) | 一种水包油型复方金霉素纳米乳 | |
CN108025080A (zh) | 含环孢霉素且无刺激性的眼药组合物及便利的制备方法 | |
CN107648181A (zh) | 一种利他唑酮磷脂复合物及其制备方法和应用 | |
WO1998013359A1 (de) | Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral und antiviral wirksamen estern von baccatin-iii-verbindungen | |
EP3302712B1 (en) | Anti-dandruf composition comprising pycnidione and epolone | |
Bamisaye et al. | Recent advances in nanoemulsion for sustainable development of farm-to-fork systems | |
Chaudhary et al. | Role of nanoemulsion as drugs delivery systems in opthalmology: A Comprehensive review | |
CN101700230B (zh) | 一种单唾液酸四己糖神经节苷酯微球及其制备方法 | |
CN104095812B (zh) | 含阿维菌素类药物可乳化油质注射剂的制备方法 | |
Tarannum et al. | Nanoparticles assisted intra and transdermic delivery of antifungal ointment: an updated review | |
CN101785757B (zh) | 一种紫杉醇自乳化制剂及其制备方法和用途 | |
Okonkwo et al. | Extraction and nanoencapsulation of ocimum gratissimum leaf extract and its anti-mycobacterial activities | |
KR100509717B1 (ko) | 주름개선 화장품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200327 Address after: 528400 Room 401, 4th floor, scientific research building, No. 10, Shennong Road, Torch Development Zone, Zhongshan City, Guangdong Province Applicant after: Guangdong saifaluo Pharmaceutical Co.,Ltd. Address before: 621000 No. 6 Kang Road, hi tech Development Zone, Sichuan, Mianyang Applicant before: SICHUAN SAIZHUO PHARMACY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230620 Address after: No.10, Shennong Road, Torch Development Zone, Zhongshan City, Guangdong Province, 528400 Patentee after: GUANGDONG JINCHENG JINSU PHARMACY Co.,Ltd. Address before: Room 401, 4th floor, scientific research building, No.10 Shennong Road, Torch Development Zone, Zhongshan City, Guangdong Province 528400 Patentee before: Guangdong saifaluo Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |